Olivier M. Dorchies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivier M. Dorchies has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Laurence A. Neff
Laboratory of Fundamental and Applied Bioenergetics, Inserm U1055, Université Grenoble Alpes, Grenoble, France
4 shared publications Elinam Gayi
Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Lausanne, University of Geneva, CMU 5-6, Rue Michel-Servet 1, Geneva, 1211, Switzerland
3 shared publications- Hesham M. Ismail
Pharmaceutical Biochemistry/Chemistry Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
3 shared publications - Leonardo Scapozza
Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
3 shared publications - Laurent Arthur Decosterd
Laboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland
2 shared publications - Urs Théodore Rüegg
Geneva-Lausanne School of Pharmaceutical Sciences, University of Geneva, CH 1211 Geneva, Switzerland
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in Archives of Oral Biology
- Vol. 189, 106642
Remodelling of intrinsic tongue muscles in a Duchenne muscular dystrophy mouse model: regional differences in fibre size and regeneration
- 3 June 2026
- Published by Elsevier in Archives of Oral Biology
- Vol. 189, 106642
Open AccessRemodelling of intrinsic tongue muscles in a Duchenne muscular dystrophy mouse model: regional differences in fibre size and regeneration
- Open Access
- 24 April 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (6) , 1215-1227
TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT
The TREAT-NMD Advisory Committee for Therapeutics (TACT) provides academic and industry applicants involved in therapy development in the neuromuscular disease (NMD) space with constructive, multidisciplinary expert advice in order to help derisk NMD drug development and avoid potential therapies entering clinical trials prematurely and to improve trial design. The ultimate goal of TACT is to reduce the risk of type 1 errors (concluding a treatment is effective, while it is not), type 2 errors (concluding a treatment is not effective, while it is), or risks of questions and regulatory rejections later on in development. TACT celebrated its 15 th birthday in 2024. From 2009–2024 TACT reviewed 90 applications, 68 from Industry and 22 from Academia. This perspective paper summarizes how TACT has evolved from its initiation. Furthermore, based on our experience, we list recurrent mistakes, such as not collecting sufficient information in pre-clinical studies, omitting wild type references in animal studies and choosing the wrong or too many outcome measures in clinical trials. By sharing common errors in preclinical and clinical trial design and providing lessons learned we aim to further improve therapy development in the NMD space.
- 24 April 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (6) , 1215-1227
Open AccessTREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT
The TREAT-NMD Advisory Committee for Therapeutics (TACT) provides academic and industry applicants involved in therapy development in the neuromuscular disease (NMD) space with constructive, multidisciplinary expert advice in order to help derisk NMD drug development and avoid potential therapies entering clinical trials prematurely and to improve trial design. The ultimate goal of TACT is to reduce the risk of type 1 errors (concluding a treatment is effective, while it is not), type 2 errors (concluding a treatment is not effective, while it is), or risks of questions and regulatory rejections later on in development. TACT celebrated its 15 th birthday in 2024. From 2009–2024 TACT reviewed 90 applications, 68 from Industry and 22 from Academia. This perspective paper summarizes how TACT has evolved from its initiation. Furthermore, based on our experience, we list recurrent mistakes, such as not collecting sufficient information in pre-clinical studies, omitting wild type references in animal studies and choosing the wrong or too many outcome measures in clinical trials. By sharing common errors in preclinical and clinical trial design and providing lessons learned we aim to further improve therapy development in the NMD space.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Degenerative Neurological and Neuromuscular Disease
- Vol. ume 15, 1-15
A Hypothesized Therapeutic Role of (Z)-Endoxifen in Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) is an inherited, X-linked disorder that is progressive, debilitating, and ultimately fatal. The current therapeutic landscape offers no cures, but does include palliative treatments that delay disease progression, and there is progress on genetic therapies that have the promise to be curative. There is much room for new therapies, and foundational work with the estrogen receptor modulator tamoxifen suggests the potential of a unique spectrum of therapeutic benefit from endoxifen, a metabolite of tamoxifen. Here we describe the potential for this new DMD therapy in the context of the overall DMD therapeutic landscape.
- 1 March 2025
- Published by Taylor & Francis in Degenerative Neurological and Neuromuscular Disease
- Vol. ume 15, 1-15
Open AccessA Hypothesized Therapeutic Role of (Z)-Endoxifen in Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) is an inherited, X-linked disorder that is progressive, debilitating, and ultimately fatal. The current therapeutic landscape offers no cures, but does include palliative treatments that delay disease progression, and there is progress on genetic therapies that have the promise to be curative. There is much room for new therapies, and foundational work with the estrogen receptor modulator tamoxifen suggests the potential of a unique spectrum of therapeutic benefit from endoxifen, a metabolite of tamoxifen. Here we describe the potential for this new DMD therapy in the context of the overall DMD therapeutic landscape.
- Open Access
- 1 August 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (8) , 2514-2534
Multi-omics comparisons of different forms of centronuclear myopathies and the effects of several therapeutic strategies
- 1 August 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (8) , 2514-2534
Open AccessMulti-omics comparisons of different forms of centronuclear myopathies and the effects of several therapeutic strategies
- Open Access
- 1 June 2019
- Published by EDP Sciences in Les Cahiers de Myologie
- No. 19,p. 25-27
Le tamoxifène dans l’arsenal thérapeutique des maladies neuromusculaires ?
Compte tenu des coûts importants du développement clinique de nouvelles molécules et de la lenteur de la découverte de nouveaux traitements, repositionner un médicament « ancien » dans une nouvelle indication s’avère parfois une solution intéressante. Elle implique de réutiliser un composé dont la sécurité et la tolérance ont déjà été démontrées, avec potentiellement une réduction des délais et des budgets de développement, mais aussi une augmentation des chances de succès. Le tamoxifène, utilisé en oncologie depuis près de 40 ans, est ainsi considéré comme un candidat médicament prometteur pour la dystrophie musculaire de Duchenne mais aussi pour la myopathie myotubulaire liée à l’X. Point d’étape…
- 1 June 2019
- Published by EDP Sciences in Les Cahiers de Myologie
- No. 19,p. 25-27
Open AccessLe tamoxifène dans l’arsenal thérapeutique des maladies neuromusculaires ?
Compte tenu des coûts importants du développement clinique de nouvelles molécules et de la lenteur de la découverte de nouveaux traitements, repositionner un médicament « ancien » dans une nouvelle indication s’avère parfois une solution intéressante. Elle implique de réutiliser un composé dont la sécurité et la tolérance ont déjà été démontrées, avec potentiellement une réduction des délais et des budgets de développement, mais aussi une augmentation des chances de succès. Le tamoxifène, utilisé en oncologie depuis près de 40 ans, est ainsi considéré comme un candidat médicament prometteur pour la dystrophie musculaire de Duchenne mais aussi pour la myopathie myotubulaire liée à l’X. Point d’étape…
- Open Access
- 19 November 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 4848
Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy
X-linked myotubular myopathy (XLMTM, also known as XLCNM) is a severe congenital muscular disorder due to mutations in the myotubularin gene, MTM1. It is characterized by generalized hypotonia, leading to neonatal death of most patients. No specific treatment exists. Here, we show that tamoxifen, a well-known drug used against breast cancer, rescues the phenotype of Mtm1-deficient mice. Tamoxifen increases lifespan several-fold while improving overall motor function and preventing disease progression including lower limb paralysis. Tamoxifen corrects functional, histological and molecular hallmarks of XLMTM, with improved force output, myonuclei positioning, myofibrillar structure, triad number, and excitation-contraction coupling. Tamoxifen normalizes the expression level of the XLMTM disease modifiers DNM2 and PI3KC2B, likely contributing to the phenotypic rescue. Our findings demonstrate that tamoxifen is a promising candidate for clinical evaluation in XLMTM patients.
- 19 November 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 4848
Open AccessTamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy
X-linked myotubular myopathy (XLMTM, also known as XLCNM) is a severe congenital muscular disorder due to mutations in the myotubularin gene, MTM1. It is characterized by generalized hypotonia, leading to neonatal death of most patients. No specific treatment exists. Here, we show that tamoxifen, a well-known drug used against breast cancer, rescues the phenotype of Mtm1-deficient mice. Tamoxifen increases lifespan several-fold while improving overall motor function and preventing disease progression including lower limb paralysis. Tamoxifen corrects functional, histological and molecular hallmarks of XLMTM, with improved force output, myonuclei positioning, myofibrillar structure, triad number, and excitation-contraction coupling. Tamoxifen normalizes the expression level of the XLMTM disease modifiers DNM2 and PI3KC2B, likely contributing to the phenotypic rescue. Our findings demonstrate that tamoxifen is a promising candidate for clinical evaluation in XLMTM patients.
- Open Access
- 1 April 2018
- Published by Swiss Chemical Society in Chimia
- Vol. 72 (4) , 238-240
Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy
Drug discovery is a long, expensive and risky process. Evaluating drugs that have already been proved safe for use in humans and testing them for a new indication greatly reduces the time and monetary costs involved in finding treatments for life-threatening conditions. Here tamoxifen, a drug that is used for the treatment of breast cancer, is investigated in a mouse model of Duchenne muscular dystrophy. Tamoxifen was efficacious in countering the symptoms of the disease without affecting the underlying genetic cause. Based on these results, tamoxifen has been tested in other forms of muscle disease with success. Drug repurposing may not only be a cost-effective manner for treating a variety of diseases, it may also help us uncover common mechanisms between conditions that were previously thought to be unrelated.
- 1 April 2018
- Published by Swiss Chemical Society in Chimia
- Vol. 72 (4) , 238-240
Open AccessRepurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy
Drug discovery is a long, expensive and risky process. Evaluating drugs that have already been proved safe for use in humans and testing them for a new indication greatly reduces the time and monetary costs involved in finding treatments for life-threatening conditions. Here tamoxifen, a drug that is used for the treatment of breast cancer, is investigated in a mouse model of Duchenne muscular dystrophy. Tamoxifen was efficacious in countering the symptoms of the disease without affecting the underlying genetic cause. Based on these results, tamoxifen has been tested in other forms of muscle disease with success. Drug repurposing may not only be a cost-effective manner for treating a variety of diseases, it may also help us uncover common mechanisms between conditions that were previously thought to be unrelated.
- Open Access
- 16 September 2015
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 6, 254
Caloric restriction induces energy-sparing alterations in skeletal muscle contraction, fiber composition and local thyroid hormone metabolism that persist during catch-up fat upon refeeding
Weight regain after caloric restriction results in accelerated fat storage in adipose tissue. This catch-up fat phenomenon is postulated to result partly from suppressed skeletal muscle thermogenesis, but the underlying mechanisms are elusive. We investigated whether the reduced rate of skeletal muscle contraction-relaxation cycle that occurs after caloric restriction persists during weight recovery and could contribute to catch-up fat. Using a rat model of semistarvation-refeeding, in which fat recovery is driven by suppressed thermogenesis, we show that contraction and relaxation of leg muscles are slower after both semistarvation and refeeding. These effects are associated with (i) higher expression of muscle deiodinase type 3 (DIO3) which inactivates tri-iodothyronine (T3), and lower expression of T3-activating enzyme, deiodinase type 2 (DIO2), (ii) slower net formation of T3 from its T4 precursor in muscles, and (iii) accumulation of slow fibers at the expense of fast fibers. These semistarvation-induced changes persisted during recovery and correlated with impaired expression of transcription factors involved in slow-twitch muscle development. We conclude that diminished muscle thermogenesis following caloric restriction results from reduced muscle T3 levels, alteration in muscle-specific transcription factors, and fast-to-slow fiber shift causing slower contractility. Energy-sparing effects persist during weight recovery and likely contribute to catch-up fat.
- 16 September 2015
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 6, 254
Open AccessCaloric restriction induces energy-sparing alterations in skeletal muscle contraction, fiber composition and local thyroid hormone metabolism that persist during catch-up fat upon refeeding
Weight regain after caloric restriction results in accelerated fat storage in adipose tissue. This catch-up fat phenomenon is postulated to result partly from suppressed skeletal muscle thermogenesis, but the underlying mechanisms are elusive. We investigated whether the reduced rate of skeletal muscle contraction-relaxation cycle that occurs after caloric restriction persists during weight recovery and could contribute to catch-up fat. Using a rat model of semistarvation-refeeding, in which fat recovery is driven by suppressed thermogenesis, we show that contraction and relaxation of leg muscles are slower after both semistarvation and refeeding. These effects are associated with (i) higher expression of muscle deiodinase type 3 (DIO3) which inactivates tri-iodothyronine (T3), and lower expression of T3-activating enzyme, deiodinase type 2 (DIO2), (ii) slower net formation of T3 from its T4 precursor in muscles, and (iii) accumulation of slow fibers at the expense of fast fibers. These semistarvation-induced changes persisted during recovery and correlated with impaired expression of transcription factors involved in slow-twitch muscle development. We conclude that diminished muscle thermogenesis following caloric restriction results from reduced muscle T3 levels, alteration in muscle-specific transcription factors, and fast-to-slow fiber shift causing slower contractility. Energy-sparing effects persist during weight recovery and likely contribute to catch-up fat.
- Open Access
- 1 February 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 182 (2) , 485-504
The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular Dystrophy
- 1 February 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 182 (2) , 485-504
Open AccessThe Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular Dystrophy